South Korea will resume administrating the Oxford-AstraZeneca COVID-19 vaccine to all eligible people between the ages of 30 and 60. The vaccine's use was suspended as European Union reviewed cases of blood clotting in adults. People under 30 will still be excluded because the benefits of the shot don't outweigh the risks for that age group, an official statement said.